- Home
- VSTM
VSTM
Verastem Inc.
as 07-26-2024 4:00pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 84.1M | IPO Year: | 2012 |
| Target Price: | $20.21 | AVG Volume (30 days): | 805.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.54 - $14.22 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 13647.06% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Jul 9 '24 | Sell | $2.62 | 7 | $18.34 | 47,560 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Jun 18 '24 | Sell | $3.16 | 67 | $211.72 | 47,318 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Jun 17 '24 | Sell | $3.21 | 183 | $587.43 | 236,063 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Jun 17 '24 | Sell | $3.49 | 244 | $851.56 | 86,246 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jun 17 '24 | Sell | $3.49 | 283 | $987.67 | 27,108 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jun 17 '24 | Sell | $3.21 | 131 | $420.51 | 35,310 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Jun 17 '24 | Sell | $3.49 | 593 | $2,069.57 | 89,047 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Jun 17 '24 | Sell | $3.21 | 335 | $1,075.35 | 97,045 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Apr 5 '24 | Sell | $10.87 | 6 | $65.22 | 8,535 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 25 '24 | Sell | $12.02 | 25 | $300.50 | 8,541 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 20 '24 | Sell | $11.07 | 55 | $608.85 | 8,566 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Mar 18 '24 | Sell | $10.71 | 283 | $3,030.93 | 27,521 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Mar 18 '24 | Sell | $10.38 | 130 | $1,349.40 | 27,391 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Mar 18 '24 | Sell | $10.71 | 244 | $2,613.24 | 86,672 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Mar 18 '24 | Sell | $10.38 | 182 | $1,889.16 | 86,490 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Mar 18 '24 | Sell | $10.71 | 537 | $5,751.27 | 89,913 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Mar 18 '24 | Sell | $10.38 | 273 | $2,833.74 | 89,640 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Feb 6 '24 | Sell | $13.70 | 9,204 | $126,094.80 | 27,804 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jan 12 '24 | Sell | $10.95 | 9,204 | $100,783.80 | 37,008 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Jan 5 '24 | Sell | $8.50 | 6 | $51.00 | 8,621 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Dec 26 '23 | Sell | $8.08 | 25 | $202.00 | 8,350 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Dec 20 '23 | Sell | $7.93 | 57 | $452.01 | 8,375 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Dec 18 '23 | Sell | $7.64 | 244 | $1,864.16 | 87,099 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Dec 18 '23 | Sell | $7.73 | 183 | $1,414.59 | 86,916 | SEC Form 4 |
| Rowinsky Eric K | VSTM | Director | Sep 5 '17 | Buy | $3.84 | 2,000 | $7,680.00 | 2,000 | SEC Form 4 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating
MT Newswires
3 days ago
Top Premarket Decliners
Business Wire
3 days ago
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Business Wire
3 days ago
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Zacks
11 days ago
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
Clinical Trials Arena
12 days ago
Verastem announces dosing of first patient in trial of KRAS G12D inhibitor
MT Newswires
14 days ago
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT Newswires
15 days ago
Verastem Says First Patient Dosed in Phase 1/2 Solid Tumor Trial in China
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.